Century Therapeutics Files 8-K on Officer/Director Changes, Comp
Ticker: IPSC · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1850119
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**Century Therapeutics just filed an 8-K about executive changes or pay, so check the full details!**
AI Summary
Century Therapeutics, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 15, 2024. This filing indicates a change in leadership or executive compensation, as per Item 5.02, which covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.' While the specific details of the change are not provided in this excerpt, investors should pay attention to the full filing to understand who is leaving or joining, or how executive pay is changing, as these can impact the company's strategic direction and financial health.
Why It Matters
Changes in leadership or executive compensation can signal shifts in company strategy, performance, or financial stability, directly impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Without the full details of the Item 5.02 event, the impact on the company is unknown, ranging from minor to significant, thus posing a medium risk.
Analyst Insight
A smart investor would immediately seek out the full 8-K filing to understand the specific details of the Item 5.02 event, as changes in leadership or compensation can significantly impact future company performance and stock valuation.
Key Numbers
- $0.0001 — par value per share (par value of Century Therapeutics' Common Stock)
Key Players & Entities
- Century Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 15, 2024 (date) — date of the earliest event reported
- January 19, 2024 (date) — date the 8-K was filed
- 001-40498 (dollar_amount) — Commission File Number
- IPSC (company) — trading symbol for Common Stock
- $0.0001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- The full 8-K filing will reveal specific names of individuals involved in the Item 5.02 event. (Century Therapeutics, Inc.) — high confidence, target: N/A
- The market reaction to this 8-K will depend heavily on the specifics of the executive changes or compensation arrangements. (IPSC stock price) — medium confidence, target: N/A
FAQ
What is the specific nature of the event reported by Century Therapeutics, Inc. on January 15, 2024?
The filing indicates the event falls under Item 5.02, which covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.' The exact nature (e.g., who departed, who was appointed, or specific compensation changes) is not detailed in this excerpt.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted to the SEC on January 19, 2024, as indicated by the 'FILED AS OF DATE: 20240119'.
What is the trading symbol and the exchange where Century Therapeutics, Inc.'s common stock is registered?
Century Therapeutics, Inc.'s Common Stock trades under the symbol IPSC on the Nasdaq Global Select Market.
What is the par value of Century Therapeutics, Inc.'s common stock?
The par value of Century Therapeutics, Inc.'s common stock is $0.0001 per share.
What is the business address and phone number of Century Therapeutics, Inc.?
The business address is 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104, and the business phone number is (267) 817-5790.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-19 17:03:44
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select
Filing Documents
- tm243558d1_8k.htm (8-K) — 26KB
- 0001104659-24-005271.txt ( ) — 196KB
- ipsc-20240115.xsd (EX-101.SCH) — 3KB
- ipsc-20240115_lab.xml (EX-101.LAB) — 33KB
- ipsc-20240115_pre.xml (EX-101.PRE) — 22KB
- tm243558d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On January 15, 2024, Michael C. Diem, M.D. notified Century Therapeutics, Inc. (the " Company ") of his decision to resign as Chief Financial Officer of the Company, effective as of February 2, 2024. The Company has commenced a search for a new Chief Financial Officer. Following the effectiveness of Dr. Diem's resignation and until a new Chief Financial Officer is appointed, Douglas Carr, the Company's Senior Vice President, Finance and Operations, will serve as interim Principal Financial Officer. Dr. Diem's decision to resign from the Company was not the result of any disagreement with the Company on matters relating to the Company's operations, policies or practices.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D., MBA Name: Brent Pfeiffenberger, Pharm.D., MBA Title: Chief Executive Officer Date: January 19, 2024